These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 3802076

  • 21. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y, Saito M, Fukushima H, Takeda Y, Hara T.
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [Abstract] [Full Text] [Related]

  • 22. Similar characteristics of folate analogue transport in vitro in contrast to varying dihydrofolate reductase levels in epithelial cells at different stages of maturation in mouse small intestine.
    Sirotnak FM, Moccio DM, Yang CH.
    Cancer Res; 1984 Nov; 44(11):5204-11. PubMed ID: 6488181
    [Abstract] [Full Text] [Related]

  • 23. Accumulation and metabolism of adenallene by murine leukemia L1210 cells.
    Kessel D, Zemlicka J.
    Arch Biochem Biophys; 1994 Jan; 308(1):222-5. PubMed ID: 8311456
    [Abstract] [Full Text] [Related]

  • 24. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
    White JC, Hines LH.
    Cancer Res; 1987 Apr 01; 47(7):1820-4. PubMed ID: 3028615
    [Abstract] [Full Text] [Related]

  • 25. Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells.
    Chello PL, Sirotnak FM, Dorick DM, Donsbach RC.
    Cancer Res; 1977 Dec 01; 37(12):4297-303. PubMed ID: 922722
    [No Abstract] [Full Text] [Related]

  • 26. Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.
    Mayhew E, Papahadjopoulos D, Rustum YM, Dave C.
    Cancer Res; 1976 Dec 01; 36(12):4406-11. PubMed ID: 187321
    [Abstract] [Full Text] [Related]

  • 27. Enhancement of the antitumor activity of arabinofuranosyladenine of 2'-deoxycoformycin.
    LePage GA, Worth LS, Kimball AP.
    Cancer Res; 1976 Apr 01; 36(4):1481-5. PubMed ID: 946595
    [Abstract] [Full Text] [Related]

  • 28. Correlation of mouse tissue distribution of arabinosylcytosine in vivo with enzymatic activities in vitro.
    Ho DH.
    Drug Metab Dispos; 1976 Apr 01; 4(3):296-300. PubMed ID: 6236
    [Abstract] [Full Text] [Related]

  • 29. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells.
    Rodriguez CO, Legha JK, Estey E, Keating MJ, Gandhi V.
    Clin Cancer Res; 1997 Nov 01; 3(11):2107-13. PubMed ID: 9815603
    [Abstract] [Full Text] [Related]

  • 30. Pharmacology of combination chemotherapy of cytosine arabinoside (ara-C) and uracil arabinoside (ara-U) or tetrahydrouridine (THU) against murine leukemia L1210/0 in tumor-bearing mice.
    Avramis VI, Powell W.
    Cancer Invest; 1987 Nov 01; 5(4):293-9. PubMed ID: 3664332
    [Abstract] [Full Text] [Related]

  • 31. Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
    Ahluwalia GS, Cohen MB, Kang GJ, Arnold ST, McMahon JB, Dalal M, Wilson YA, Cooney DA, Balzarini J, Johns DG.
    Cancer Res; 1986 Sep 01; 46(9):4479-85. PubMed ID: 2425954
    [Abstract] [Full Text] [Related]

  • 32. Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.
    Walsh CT, Craig RW, Agarwal RP.
    Cancer Res; 1980 Sep 01; 40(9):3286-92. PubMed ID: 7427943
    [Abstract] [Full Text] [Related]

  • 33. Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.
    Dalal M, Plowman J, Breitman TR, Schuller HM, del Campo AA, Vistica DT, Driscoll JS, Cooney DA, Johns DG.
    Cancer Res; 1986 Feb 01; 46(2):831-8. PubMed ID: 2416433
    [Abstract] [Full Text] [Related]

  • 34. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V, Fridland A.
    Cancer Res; 1985 Aug 01; 45(8):3646-50. PubMed ID: 2410098
    [Abstract] [Full Text] [Related]

  • 35. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin.
    Cass CE, Au-Yeung TH.
    Cancer Res; 1976 Apr 01; 36(4):1486-91. PubMed ID: 944095
    [Abstract] [Full Text] [Related]

  • 36. Relationship between incorporation of 9-beta-D-arabinofuranosyladenine in L 1210 DNA and cytotoxicity.
    Kufe DW, Major PP, Munroe D, Egan M, Herrick D.
    Cancer Res; 1983 May 01; 43(5):2000-4. PubMed ID: 6831429
    [Abstract] [Full Text] [Related]

  • 37. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF, Huang P, Plunkett W, Gandhi V.
    Clin Cancer Res; 1996 Apr 01; 2(4):653-8. PubMed ID: 9816215
    [Abstract] [Full Text] [Related]

  • 38. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D.
    Toxic Rep Ser; 1995 Apr 01; 30():1-G5. PubMed ID: 12209194
    [Abstract] [Full Text] [Related]

  • 39. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability.
    Matsushita T, Ryu EK, Hong CI, MacCoss M.
    Cancer Res; 1981 Jul 01; 41(7):2707-13. PubMed ID: 7248939
    [Abstract] [Full Text] [Related]

  • 40. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
    Furusawa S, Mian AM.
    Cancer Treat Rep; 1987 May 01; 71(5):441-6. PubMed ID: 3567967
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.